NL-OMON48749撤回3 期
Phase 3b Study for Management of Ocular Side Effects in Subjects with EGFR-Amplified Glioblastoma Receiving Depatuxizumab Mafodotin (ABT-414) - M16-534
适应症
试验速览
- 阶段
- 3 期
- 状态
- 撤回
- 入组人数
- 9
研究概览
简要总结
Trial never started
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Participant has a histologically proven, World Health Organization (WHO) grade IV glioblastoma or WHO grade IV gliosarcoma.;• Tumors must demonstrate epidermal growth factor receptor (EGFR) amplification.;• Tumors must be supratentorial in location.;• Participant must have recovered from the effects of surgery, postoperative infection, and other complications; has no significant post-operative hemorrhage.;• Participant has a Karnofsky performance status (KPS) of 70 or higher.;• Participant has adequate bone marrow, renal, and hepatic function.;• Electrocardiogram without evidence of acute cardiac ischemia <= 21 days prior to randomization.;• Participant has a life expectancy of >= 3 months;•Participant has infection with hepatitis B virus (i.e., hepatitis B surface antigen) or hepatitis C virus (i.e., positive for hepatitis C antibody).
- •Subjects who have a history of hepatitis C who have documented cures after anti-viral therapy may be enrolled. Subjects with confirmed
- •positive test result for human immunodeficiency virus (HIV), with CD4 count < 200 cells/microliter are excluded. Note that subjects who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count >= 200 cells/microliter within 30 days prior to registration, as the treatments involved in this protocol may be significantly immunosuppressive.
排除标准
- •Participants with newly diagnosed Glioblastoma: has received prior chemotherapy or radiotherapy for cancer of the head and neck region; has received prior treatment with Gliadel wafers or any other intratumoral or intracavitary treatment.;• Participant has hypersensitivity to any component of Temozolomide or dacarbazine.;• Participant has received anti-cancer therapy (including chemotherapy, immunotherapy, radiotherapy, hormonal, biologic, or any investigational therapy) prior to 5 years of Study Day 1.;• Participant has clinically significant uncontrolled condition(s) as described in the protocol.;• Participant has any medical condition which in the opinion of the investigator places the participant at an unacceptably high risk for toxicities.;• Participant has had another active malignancy within the past 3 years except for any cancer considered cured or non-melanoma carcinoma of the skin.;• Participant has a history of herpetic keratitis.;• Participant is not suitable for receiving ocular steroids with conditions as described in the protocol.;• Participant has had laser-assisted in situ keratomileusis (LASIK) procedure within the last 1 year or cataract surgery within the last 3 months.;• Participant has a visual condition that compromises the ability to accurately measure visual acuity or assess visual activities of daily living (vADLs).;• Participant has infection with hepatitis B virus (i.e., hepatitis B surface antigen) or hepatitis C virus (i.e., positive for hepatitis C antibody). Subjects who have a history of hepatitis C who have documented cures after anti-viral therapy may be enrolled. Subjects with confirmed
- •positive test result for human immunodeficiency virus (HIV), with CD4 count < 200 cells/microliter are excluded. Note that subjects who are
- •HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count >= 200
- •cells/microliter within 30 days prior to registration, as the treatments involved in this protocol may be significantly immunosuppressive.
研究者
相似试验
进行中（未招募）
1 期
Study for the Management of Ocular Side Effects in Participants with Epidermal Growth Factor Receptor (EGFR)-amplified GlioblastomaReceiving Depatuxizumab Mafodotin (ABT-414)EGFR-Amplified Newly diagnosed glioblastomaMedDRA version: 20.0Level: PTClassification code 10018336Term: GlioblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-003171-64-DEAbbVie Deutschland GmbH & Co.KG90
进行中（未招募）
1 期
Study for the Management of Ocular Side Effects in Participants with Epidermal Growth Factor Receptor (EGFR)-amplified GlioblastomaReceiving Depatuxizumab Mafodotin (ABT-414)EUCTR2017-003171-64-NLAbbVie Deutschland GmbH & Co.KG40
进行中（未招募）
1 期
Study for the Management of Ocular Side Effects in Participants with Epidermal Growth Factor Receptor (EGFR)-amplified GlioblastomaReceiving Depatuxizumab Mafodotin (ABT-414)EGFR-Amplified Newly diagnosed glioblastomaMedDRA version: 20.0Level: PTClassification code 10018336Term: GlioblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-003171-64-GBAbbVie Deutschland GmbH & Co.KG90
撤回
3 期
A Phase 3b, Randomized, Double-Blind Study to Evaluate Switching from a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected SubjectsHuman Immunodeficiency visrus (HIV-1) infections10047438NL-OMON42500Gilead Sciences20
撤回
2 期
Phase 1/2 Study to Investigate the Safety, Pharmacokinetics and Efficacy of Tinostamustine, a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule, in Patients with Advanced Solid TumorsNL-OMON50797Mundipharma15